Improving Clinical Decision Making with Engaging CME, Tools, & Resources
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Signaling for Sustained Change: Spotlight on the Potential of TKIs to Deliver Durable Control of Exudative Retinal Disease
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Ashkan Abbey, MD
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Maria H. Berrocal, MD
Lejla Vajzovic, MD, FASRS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
David Chin Yee, MD, FASRS
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Deepak Sambhara, MD
GLP-1 Use and AMD Risk
Barton Lynn Blackorby, MD
Katharine Talcott, MD
Hong-Uyen Hua, MD
MH Risk Factors After RRD Repair
Avni P. Finn, MD, MBA
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Esther Lee Kim, MD
Diagnosis Delays in Stargardt Disease
Alexis Warren, MD
Jesse Sengillo, MD
Sruthi Arepalli, MD
Redefining The Cash-Pay Model in Modern Optometric Practice
Jason E. Compton, OD, FAAO
Practice Efficiency and Innovation
Jacob Lang
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Jennifer Caudle, DO, FACOFP
Michael Javaheri, MD, MSc, FASRS
From Image to Intervention: Integrating the Diagnosis into Specialty Lens Designs and Corneal Rehabilitation
Loading...
We're glad to see you're enjoying Eye Health Academy… but how about a more personalized experience?
Press cancel to remain on Eye Health Academy. Press the link below or the continue button to keep going.